{"id": "moa.assertion:71", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "T315I mutant ABL1 in p210 BCR-ABL cells resulted in retained high levels of phosphotyrosine at increasing concentrations of inhibitor STI-571, whereas wildtype appropriately received inhibition.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:44", "type": "Document", "label": "Gorre, Mercedes E., et al. \"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.\" Science 293.5531 (2001): 876-880.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1126/science.1062538"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:11423618", "doi:10.1126/science.1062538"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:pfhxkbKw2pNHnGu6sjexO8yI8RaeY4mH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Y6wbwixkMlfdp1iiNUfz_uJJN8mTz_ws", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:71", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Imatinib", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "therapeutic": "rxcui:282388"}}
{"id": "moa.assertion:73", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:45", "type": "Document", "label": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2010-12-326405"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27760149", "doi:10.1182/blood-2010-12-326405"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:HN7pqZfCz_BJy5Wz72NnE4k3GPuM_mfl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.AJ5CxkcHNRGf_fr3LGDf1x5uagW32wOi", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:73", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:74", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:45", "type": "Document", "label": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2010-12-326405"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27760149", "doi:10.1182/blood-2010-12-326405"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:sQ5e1pQ5mXy_ViQU37eDsgWe7pzIaB4i", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Y6wbwixkMlfdp1iiNUfz_uJJN8mTz_ws", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:71", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:75", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:45", "type": "Document", "label": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2010-12-326405"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27760149", "doi:10.1182/blood-2010-12-326405"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:EoSSIy6BEnbdWMAqs2tzdlWXBc6h5D4U", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.E-mdgEKR7wkrBnIr5AGxM1EvdJtENh-k", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:75", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:76", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:45", "type": "Document", "label": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2010-12-326405"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27760149", "doi:10.1182/blood-2010-12-326405"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:HolqY2qEXBhtdOkHCmMcxuoOpMmsZXe2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.yu2jVmX1vJRCJj9ie9dtAnFClAOBtQso", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:76", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:77", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:45", "type": "Document", "label": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2010-12-326405"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27760149", "doi:10.1182/blood-2010-12-326405"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:dpBIbYn8onMjgnJXwN-OhVElWEzVuD7j", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.igcDkD6pr8Q43CyTbpZHUYFfPDAhfinc", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:77", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:78", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:45", "type": "Document", "label": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2010-12-326405"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27760149", "doi:10.1182/blood-2010-12-326405"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:AXXm16RNy7leRflgX6XodTBOtyBarm7o", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VKAGNTTsyJG_GU4RE5BXQiXcQ3WCHmBG", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:80", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:45", "type": "Document", "label": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2010-12-326405"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27760149", "doi:10.1182/blood-2010-12-326405"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:PVYqghGPZzqC67e9xvyWgIjzq6hzvVV2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._axmNXw7sg3Ioelbp0wvJMoOP2HF4z6l", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:662281", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:80", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Nilotinib", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:662281"}}
{"id": "moa.assertion:81", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:45", "type": "Document", "label": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2010-12-326405"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27760149", "doi:10.1182/blood-2010-12-326405"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:Mwmbcv6EEZMyJpumIer30FDhR-kAyu8B", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2ovj9lZOEAVGQE-I0VtOkWRTsJ4CdYMk", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:662281", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Nilotinib", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:662281"}}
{"id": "moa.assertion:82", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:45", "type": "Document", "label": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2010-12-326405"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27760149", "doi:10.1182/blood-2010-12-326405"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:YdzPTzS261XXLM8NTgJ-wl_mYbq5Otcx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4gclaBcrLKEiFVK0KvrBlXkbU6orqzKL", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:662281", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:82", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Nilotinib", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:662281"}}
{"id": "moa.assertion:83", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:45", "type": "Document", "label": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2010-12-326405"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27760149", "doi:10.1182/blood-2010-12-326405"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:dQ7M_yu50y8Yq98bAhBmBO615Dv9ATJT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cnwDSpUl9Dgu1gETE7R529PGWLnMIXQu", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:662281", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:83", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Nilotinib", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:662281"}}
{"id": "moa.assertion:84", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:45", "type": "Document", "label": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2010-12-326405"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27760149", "doi:10.1182/blood-2010-12-326405"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:peyUS1O8f0Z-bi8zgzRDQQ4TsN7wIMRV", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.YDMyfThCgToI4BXV1wP1FvJ5NqOBO-NY", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:662281", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:84", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Nilotinib", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:662281"}}
{"id": "moa.assertion:85", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:45", "type": "Document", "label": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2010-12-326405"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27760149", "doi:10.1182/blood-2010-12-326405"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:50K8aS2ZFKZHlsJBVdhMV4lZYusiUzgz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.t13vbgoVZHdbn6JHD6Rc19yHSw7_diRq", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:662281", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:85", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Nilotinib", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:662281"}}
{"id": "moa.assertion:86", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:Nd6-pH3PD8j_ueRBmOom9o8hKM3axIb4", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4gclaBcrLKEiFVK0KvrBlXkbU6orqzKL", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:82", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:87", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:SYk5h1Yt0iVlUJPjR_LRm9C62INtGPRi", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._axmNXw7sg3Ioelbp0wvJMoOP2HF4z6l", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:80", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:88", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:39PcyOW_4vXYNFcdgmcbcRekermpiDlZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2ovj9lZOEAVGQE-I0VtOkWRTsJ4CdYMk", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:89", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:_qJPDtOrKYGb5dK0LS2VflSwalRCJoNX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cnwDSpUl9Dgu1gETE7R529PGWLnMIXQu", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:83", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:90", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:AFb8-cTK7oSVRIxFk9b8RJwXJoHXi5eb", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.YDMyfThCgToI4BXV1wP1FvJ5NqOBO-NY", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:84", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:91", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:BNrLyB50cFt-u4UgUiMUuuYtnSR9nDhc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.t13vbgoVZHdbn6JHD6Rc19yHSw7_diRq", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:85", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:92", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:_fAS8zwrBJl1ENC4iKbXVUhOCh12KzOx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.E-mdgEKR7wkrBnIr5AGxM1EvdJtENh-k", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:662281", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:75", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Nilotinib", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:662281"}}
{"id": "moa.assertion:93", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:ZR2zgwz72bTLUZ-HVEliHRRljBdHfCAK", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.yu2jVmX1vJRCJj9ie9dtAnFClAOBtQso", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:662281", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:76", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Nilotinib", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:662281"}}
{"id": "moa.assertion:94", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:czfG4aHlfgG-vmQOKIYsG3oK5rh2MIbj", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.igcDkD6pr8Q43CyTbpZHUYFfPDAhfinc", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:662281", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:77", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Nilotinib", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:662281"}}
{"id": "moa.assertion:95", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:F31WN2fyqAoD7K2CbRNFt9LZtqed-gJa", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VKAGNTTsyJG_GU4RE5BXQiXcQ3WCHmBG", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:662281", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Nilotinib", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:662281"}}
{"id": "moa.assertion:96", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:7bWqO7usUaK-cDILN2wP-t8b_qbDgfhz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.AJ5CxkcHNRGf_fr3LGDf1x5uagW32wOi", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:662281", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:73", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Nilotinib", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:662281"}}
{"id": "moa.assertion:97", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:_VNdc4siNqRV68_NfttHj3mAAhG3x5Mt", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.X1i43DenHO8W7EunVNxyyrMAejeltRtc", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:662281", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:97", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Nilotinib", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:662281"}}
{"id": "moa.assertion:98", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:9tGELZGNUN1t6XEgbcqnMoAZ2i1ujnTj", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._axmNXw7sg3Ioelbp0wvJMoOP2HF4z6l", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1307619", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:80", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Bosutinib", "type": "TherapeuticDescriptor", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "DiseaseDescriptor", "label": "chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1307619"}}
{"id": "moa.assertion:99", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:6G4Bo3VynRSlU3h7X4P9DhFOTWO6p3rK", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2ovj9lZOEAVGQE-I0VtOkWRTsJ4CdYMk", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1307619", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Bosutinib", "type": "TherapeuticDescriptor", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "DiseaseDescriptor", "label": "chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1307619"}}
{"id": "moa.assertion:100", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:izZVURouh8ug2kAJYUkxDCGVKMV7WoHu", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.E-mdgEKR7wkrBnIr5AGxM1EvdJtENh-k", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1307619", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:75", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Bosutinib", "type": "TherapeuticDescriptor", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "DiseaseDescriptor", "label": "chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1307619"}}
{"id": "moa.assertion:101", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:CvOP2vnFucQhk2m6vEOUalUCNuR3JoAL", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.yu2jVmX1vJRCJj9ie9dtAnFClAOBtQso", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1307619", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:76", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Bosutinib", "type": "TherapeuticDescriptor", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "DiseaseDescriptor", "label": "chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1307619"}}
{"id": "moa.assertion:102", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:q6TKP2NgU7THNvLh6ZbYz0Xhy5m28-s_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.igcDkD6pr8Q43CyTbpZHUYFfPDAhfinc", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1307619", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:77", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Bosutinib", "type": "TherapeuticDescriptor", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "DiseaseDescriptor", "label": "chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1307619"}}
{"id": "moa.assertion:103", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:X4zCBKrd9eXpRQKC5BUVSEEnq79oEdJH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VKAGNTTsyJG_GU4RE5BXQiXcQ3WCHmBG", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1307619", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Bosutinib", "type": "TherapeuticDescriptor", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "DiseaseDescriptor", "label": "chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1307619"}}
{"id": "moa.assertion:104", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:FzNHG7TSmazMh53RcseG9kgWhm4byLsf", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cnwDSpUl9Dgu1gETE7R529PGWLnMIXQu", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1307619", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:83", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Bosutinib", "type": "TherapeuticDescriptor", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "DiseaseDescriptor", "label": "chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1307619"}}
{"id": "moa.assertion:105", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:TmcdQctGjT1yzr5w-ffTP-LaeTqz_Ftb", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.YDMyfThCgToI4BXV1wP1FvJ5NqOBO-NY", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1307619", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:84", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Bosutinib", "type": "TherapeuticDescriptor", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "DiseaseDescriptor", "label": "chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1307619"}}
{"id": "moa.assertion:106", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:GTSAYQ5SlyAnoYBHpr1jqRpapvoVN1Ky", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.AJ5CxkcHNRGf_fr3LGDf1x5uagW32wOi", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1307619", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:73", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Bosutinib", "type": "TherapeuticDescriptor", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "DiseaseDescriptor", "label": "chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1307619"}}
{"id": "moa.assertion:107", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:QP2SG3CVwM1FpciV610IzakkF36hYEeI", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4gclaBcrLKEiFVK0KvrBlXkbU6orqzKL", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1307619", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:82", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Bosutinib", "type": "TherapeuticDescriptor", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "DiseaseDescriptor", "label": "chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1307619"}}
{"id": "moa.assertion:108", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:3KgKQdN9ZkWDz2vE82-IFbac_f29DD_-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Y6wbwixkMlfdp1iiNUfz_uJJN8mTz_ws", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1364347", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:108", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Ponatinib", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1364347"}}
{"id": "moa.assertion:109", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:jNhHd3oihM2wx1uNpc3eOHy8aS3Ax9RY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Y6wbwixkMlfdp1iiNUfz_uJJN8mTz_ws", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546446", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:108", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Omacetaxine", "type": "TherapeuticDescriptor", "label": "Omacetaxine", "therapeutic": "rxcui:1546446"}}
{"id": "moa.assertion:110", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:46", "type": "Document", "label": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:BNrLyB50cFt-u4UgUiMUuuYtnSR9nDhc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.t13vbgoVZHdbn6JHD6Rc19yHSw7_diRq", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "subject_descriptor": "moa.variant:85", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACML", "type": "DiseaseDescriptor", "label": "Chronic Myelogenous Leukemia", "xrefs": ["oncotree:CML"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "moa.normalize.therapy:Dasatinib", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "therapeutic": "rxcui:1546019"}}
{"id": "moa.assertion:115", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:48", "type": "Document", "label": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/2159-8290.CD-13-0846"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:24675041", "doi:10.1158/2159-8290.CD-13-0846"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ezjoe31LLZzuzNGkfEsnH-QeWLuuBIY-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.26hK4cuCiUr51PE7xCN6hUMnffMHIEC2", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1535457", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:115", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Ceritinib", "type": "TherapeuticDescriptor", "label": "Ceritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1535457"}}
{"id": "moa.assertion:116", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:48", "type": "Document", "label": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/2159-8290.CD-13-0846"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:24675041", "doi:10.1158/2159-8290.CD-13-0846"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:p8TlgS77jdcNorTE9Qc7fHtfATKZNdYg", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RSM_8hMJqGUJzH_VEJrENXkILKx0c4eP", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1535457", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:116", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Ceritinib", "type": "TherapeuticDescriptor", "label": "Ceritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1535457"}}
{"id": "moa.assertion:117", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:48", "type": "Document", "label": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/2159-8290.CD-13-0846"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:24675041", "doi:10.1158/2159-8290.CD-13-0846"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:SGj8Lx2Diqi3hP9EpCxWwcfmQWOtxlWI", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.0KSewJJCSGoKAgBvo-DpKEY_t76-ln6z", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1535457", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:117", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Ceritinib", "type": "TherapeuticDescriptor", "label": "Ceritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1535457"}}
{"id": "moa.assertion:118", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:48", "type": "Document", "label": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/2159-8290.CD-13-0846"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:24675041", "doi:10.1158/2159-8290.CD-13-0846"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:c-7j3N_bBs8LUDRCZdqY6Eil8Hi1mTC1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ATlbEay6yDzORVbqgPnYmzY9f8sdqFQ9", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1535457", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:118", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Ceritinib", "type": "TherapeuticDescriptor", "label": "Ceritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1535457"}}
{"id": "moa.assertion:119", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:48", "type": "Document", "label": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/2159-8290.CD-13-0846"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:24675041", "doi:10.1158/2159-8290.CD-13-0846"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:fw3OyKPLHiLUcKJDdTWkNacyfIDjuXCa", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CdANEOO4ttDtDl8rYm8yiqlUmTFWy0HB", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1535457", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:119", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Ceritinib", "type": "TherapeuticDescriptor", "label": "Ceritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1535457"}}
{"id": "moa.assertion:120", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:49", "type": "Document", "label": "Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-14-1220"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:25320358", "doi:10.1158/1078-0432.CCR-14-1220"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:rFZYMpjJfm0bd6YEUDj6Qdr1fo1hNzf4", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.oY-xQFs-CbOZJevfEPiEw8XNI8WaGH0j", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1100071", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2919", "type": "Disease"}}, "subject_descriptor": "moa.variant:120", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3APRAD", "type": "DiseaseDescriptor", "label": "Prostate Adenocarcinoma", "xrefs": ["oncotree:PRAD"], "disease": "ncit:C2919"}, "object_descriptor": {"id": "moa.normalize.therapy:Abiraterone", "type": "TherapeuticDescriptor", "label": "Abiraterone", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:658", "type": "DiseaseDescriptor", "label": "Prostate cancer", "disease": "ncit:C7378"}]}}], "therapeutic": "rxcui:1100071"}}
{"id": "moa.assertion:121", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:49", "type": "Document", "label": "Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-14-1220"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:25320358", "doi:10.1158/1078-0432.CCR-14-1220"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:7ZvUKyzcO02t8ccOW7IqykFc2EUpavrJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Pe8-dLhAyJkgsoouX5oOC3hoj6z9Z3wo", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1100071", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2919", "type": "Disease"}}, "subject_descriptor": "moa.variant:121", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3APRAD", "type": "DiseaseDescriptor", "label": "Prostate Adenocarcinoma", "xrefs": ["oncotree:PRAD"], "disease": "ncit:C2919"}, "object_descriptor": {"id": "moa.normalize.therapy:Abiraterone", "type": "TherapeuticDescriptor", "label": "Abiraterone", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:658", "type": "DiseaseDescriptor", "label": "Prostate cancer", "disease": "ncit:C7378"}]}}], "therapeutic": "rxcui:1100071"}}
{"id": "moa.assertion:122", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:50", "type": "Document", "label": "Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1172/JCI72763"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:24569458", "doi:10.1172/JCI72763"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:3nZcSFZbxUrlPTshTQLLElZk0HUwESV2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NcfHbQ_k1M8S4zdJ9JAhe1qFBaBXQIil", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:495881", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:122", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Sorafenib", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "therapeutic": "rxcui:495881"}}
{"id": "moa.assertion:134", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:55", "type": "Document", "label": "Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1016/j.tranon.2017107"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:28182994", "doi:10.1016/j.tranon.2017107"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:5-Tp7GQ4RzsY-eE63w7IzB2PVzKM5ScC", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.iolPc7iLP88pE9jqw2yrnXptib7hTyM0", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1597582", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C5105", "type": "Disease"}}, "subject_descriptor": "moa.variant:134", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACOADREAD", "type": "DiseaseDescriptor", "label": "Colorectal Adenocarcinoma", "xrefs": ["oncotree:COADREAD"], "disease": "ncit:C5105"}, "object_descriptor": {"id": "moa.normalize.therapy:Olaparib", "type": "TherapeuticDescriptor", "label": "Olaparib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D010051", "type": "DiseaseDescriptor", "label": "Ovarian Neoplasms", "disease": "ncit:C7431"}]}}], "therapeutic": "rxcui:1597582"}}
{"id": "moa.assertion:149", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:60", "type": "Document", "label": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:axBNVpF1a3qG7LBfm6vO0kBlRo7YNcpZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1424911", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Dabrafenib", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1424911"}}
{"id": "moa.assertion:150", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:60", "type": "Document", "label": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:pszxvq2klgdS8gFUDix0DGw5akTv4gTF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.tcd:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Dabrafenib", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1424911"}, {"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}]}}
{"id": "moa.assertion:151", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:60", "type": "Document", "label": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:0547u-q83RGm0HNMzIZxoFbu51yDHgyx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cxfjgf47lCYesVEe7nvEMqHLxqh2eliW", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:151", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.tcd:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Dabrafenib", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1424911"}, {"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}]}}
{"id": "moa.assertion:152", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:60", "type": "Document", "label": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:pszxvq2klgdS8gFUDix0DGw5akTv4gTF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.tcd:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Dabrafenib", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1424911"}, {"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}]}}
{"id": "moa.assertion:153", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:60", "type": "Document", "label": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:0547u-q83RGm0HNMzIZxoFbu51yDHgyx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cxfjgf47lCYesVEe7nvEMqHLxqh2eliW", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:151", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.tcd:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Dabrafenib", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1424911"}, {"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}]}}
{"id": "moa.assertion:154", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E, as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:60", "type": "Document", "label": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:fgXM1I7Z7ZVCgcL1lRHMDrX5UhaxO_ua", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.tcd:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Dabrafenib", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1424911"}, {"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}]}}
{"id": "moa.assertion:155", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:61", "type": "Document", "label": "Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:8_L3X6Ige9-6uWgvdVvBkQiLIvOK6dZV", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1425098", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}}
{"id": "moa.assertion:156", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:61", "type": "Document", "label": "Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:5flWULM16OL3R6iAz07Z5pRlSjjKHrU0", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cxfjgf47lCYesVEe7nvEMqHLxqh2eliW", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1425098", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:151", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}}
{"id": "moa.assertion:157", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600K mutation, as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:62", "type": "Document", "label": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:gr74n7VqClXEyN4Lm9Hrp15t_MAYJfLl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cxfjgf47lCYesVEe7nvEMqHLxqh2eliW", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2049106", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:151", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Encorafenib", "type": "TherapeuticDescriptor", "label": "Encorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D008545", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}]}}], "therapeutic": "rxcui:2049106"}}
{"id": "moa.assertion:158", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:62", "type": "Document", "label": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:AYNxOTAXGwRrTftJGUB0P4nJ5O_H_oIc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2049106", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Encorafenib", "type": "TherapeuticDescriptor", "label": "Encorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D008545", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}]}}], "therapeutic": "rxcui:2049106"}}
{"id": "moa.assertion:159", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:62", "type": "Document", "label": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:LgtRmnYf3XjmswInlRuVpAknqjqL7Mz2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:2049106", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C5105", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACOADREAD", "type": "DiseaseDescriptor", "label": "Colorectal Adenocarcinoma", "xrefs": ["oncotree:COADREAD"], "disease": "ncit:C5105"}, "object_descriptor": {"id": "moa.tcd:zBda4sO3iQLExj5SB8VTPzPLaPoWefiP", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:2049106", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Cetuximab", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "therapeutic": "rxcui:318341"}, {"id": "moa.normalize.therapy:Encorafenib", "type": "TherapeuticDescriptor", "label": "Encorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D008545", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}]}}], "therapeutic": "rxcui:2049106"}]}}
{"id": "moa.assertion:160", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:63", "type": "Document", "label": "Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:b3f7MP6XtAP-IiLVqnnnlrIk2qsy_Zs_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}}
{"id": "moa.assertion:161", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:64", "type": "Document", "label": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:jChX8IFaF4QkfAXVXmgHT4RAM7o9YUxa", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C5105", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACOADREAD", "type": "DiseaseDescriptor", "label": "Colorectal Adenocarcinoma", "xrefs": ["oncotree:COADREAD"], "disease": "ncit:C5105"}, "object_descriptor": {"id": "moa.normalize.therapy:Panitumumab", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "therapeutic": "rxcui:263034"}}
{"id": "moa.assertion:163", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:66", "type": "Document", "label": "National Comprehensive Cancer Network. Melanoma NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:b3f7MP6XtAP-IiLVqnnnlrIk2qsy_Zs_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}}
{"id": "moa.assertion:164", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:66", "type": "Document", "label": "National Comprehensive Cancer Network. Melanoma NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:axBNVpF1a3qG7LBfm6vO0kBlRo7YNcpZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1424911", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Dabrafenib", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1424911"}}
{"id": "moa.assertion:165", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:66", "type": "Document", "label": "National Comprehensive Cancer Network. Melanoma NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:8S_GJT2rwb8YwHK9I-vyyagIPGqJJeay", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1722365", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.tcd:dhs2LkZmpoTUpE6XlcACT7zTBbnvfnX9", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1722365", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Cobimetinib", "type": "TherapeuticDescriptor", "label": "Cobimetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1722365"}, {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}]}}
{"id": "moa.assertion:166", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:66", "type": "Document", "label": "National Comprehensive Cancer Network. Melanoma NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:pszxvq2klgdS8gFUDix0DGw5akTv4gTF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.tcd:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Dabrafenib", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1424911"}, {"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}]}}
{"id": "moa.assertion:167", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "U.S. Food and Drug Administration granted regular approvals to dabrafenib and trametinib, administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:67", "type": "Document", "label": "Center for Drug Evaluation and Research. Approved Drugs - FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation. U S Food and Drug Administration Home Page. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm564331.htm.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm564331.htm"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:fgXM1I7Z7ZVCgcL1lRHMDrX5UhaxO_ua", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.tcd:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Dabrafenib", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1424911"}, {"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}]}}
{"id": "moa.assertion:168", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:68", "type": "Document", "label": "Amin A, Lawson DH, Salama AK, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1186/s40425-016-0148-7"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27532019", "doi:10.1186/s40425-016-0148-7", "nct:NCT01673854"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:O-0P3EzRMrrnlK3WpebZsC0hipbJ8SQ6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1094833", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.tcd:FKTdlTdqAvhIQciAr34sdnBlday3jJMR", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Combination therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1094833", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Ipilimumab", "type": "TherapeuticDescriptor", "label": "Ipilimumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D008545", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1094833"}, {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}]}}
{"id": "moa.assertion:169", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:68", "type": "Document", "label": "Amin A, Lawson DH, Salama AK, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1186/s40425-016-0148-7"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27532019", "doi:10.1186/s40425-016-0148-7", "nct:NCT01673854"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:O-0P3EzRMrrnlK3WpebZsC0hipbJ8SQ6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1094833", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.tcd:FKTdlTdqAvhIQciAr34sdnBlday3jJMR", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Combination therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1094833", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Ipilimumab", "type": "TherapeuticDescriptor", "label": "Ipilimumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D008545", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1094833"}, {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}]}}
{"id": "moa.assertion:170", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Administration of bevacizumab in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:69", "type": "Document", "label": "Caporali S, Alvino E, Lacal PM, et al. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016;49(3):1164-74.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.3892/ijo.2016.3594"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27572939", "doi:10.3892/ijo.2016.3594"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:mBim-jCt3zkAxDuUwDLSmkDGSq1baMrA", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2046138", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Bevacizumab", "type": "TherapeuticDescriptor", "label": "Bevacizumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D003110", "type": "DiseaseDescriptor", "label": "Colonic Neoplasms", "disease": "ncit:C2953"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D002289", "type": "DiseaseDescriptor", "label": "Carcinoma, Non-Small-Cell Lung", "disease": "ncit:C2926"}, {"id": "mesh:D005909", "type": "DiseaseDescriptor", "label": "Glioblastoma", "disease": "ncit:C3058"}, {"id": "mesh:D002292", "type": "DiseaseDescriptor", "label": "Carcinoma, Renal Cell", "disease": "mondo:0005086"}, {"id": "mesh:D002583", "type": "DiseaseDescriptor", "label": "Uterine Cervical Neoplasms", "disease": "ncit:C9311"}]}}], "therapeutic": "rxcui:2046138"}}
{"id": "moa.assertion:171", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Administration of GSK2126458A, a PI3K/AKT/mTOR pathway inhibitor, in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:69", "type": "Document", "label": "Caporali S, Alvino E, Lacal PM, et al. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016;49(3):1164-74.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.3892/ijo.2016.3594"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27572939", "doi:10.3892/ijo.2016.3594"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:wx7khtAJz4vgj3SCyvkYlXPRVHrE87df", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C88270", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Omipalisib", "type": "TherapeuticDescriptor", "label": "Omipalisib", "therapeutic": "ncit:C88270"}}
{"id": "moa.assertion:173", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Three human melanoma cell lines displayed sensitivity to bleomycin, particularly when co-administered with human interferon-beta gene or herpes simplex virus thymidine kinase/ganciclovir suicide gene lipofection.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:71", "type": "Document", "label": "Fondello C, Agnetti L, Villaverde MS, Simian M, Glikin GC, Finocchiaro LM. The combination of bleomycin with suicide or interferon-beta gene transfer is able to efficiently eliminate human melanoma tumor initiating cells. Biomed Pharmacother. 2016;83:290-301.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1016/j.biopha.2016638"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27399807", "doi:10.1016/j.biopha.2016638"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:sUHHPoqfYcHb7oO4GGjOMkFbxlqTXnL3", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1622", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Bleomycin", "type": "TherapeuticDescriptor", "label": "Bleomycin", "therapeutic": "rxcui:1622"}}
{"id": "moa.assertion:175", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:73", "type": "Document", "label": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1056/NEJMoa1502309"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:26287849", "doi:10.1056/NEJMoa1502309", "nct:NCT01524978"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:CNe56nqeGQLM5oQXXx2ZTlZohrgVCMQ3", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3107", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ALCH", "type": "DiseaseDescriptor", "label": "Langerhans Cell Histiocytosis", "xrefs": ["oncotree:LCH"], "disease": "ncit:C3107"}, "object_descriptor": {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}}
{"id": "moa.assertion:176", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:73", "type": "Document", "label": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1056/NEJMoa1502309"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:26287849", "doi:10.1056/NEJMoa1502309", "nct:NCT01524978"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:Y9qMlvY4gURd463Kn-5lOGMFCyo2LAAC", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53972", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AECD", "type": "DiseaseDescriptor", "label": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease", "xrefs": ["oncotree:ECD"], "disease": "ncit:C53972"}, "object_descriptor": {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}}
{"id": "moa.assertion:177", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:73", "type": "Document", "label": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1056/NEJMoa1502309"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:26287849", "doi:10.1056/NEJMoa1502309", "nct:NCT01524978"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:PX2KF06FDLt2fBuKmp2SdmjhWlge3i-Q", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}}
{"id": "moa.assertion:178", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Study of a patient-derived orthotopic xenograft (PDOX) model suggests some vemurafenib-resistant BRAF-V600E-mutated melanomas may be sensitive to trametinib (but not cobimetinib) treatment.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:74", "type": "Document", "label": "Kawaguchi K, Murakami T, Chmielowski B, et al. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget. 2016;", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.18632/oncotarget.12328"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27690220", "doi:10.18632/oncotarget.12328"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:8_L3X6Ige9-6uWgvdVvBkQiLIvOK6dZV", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1425098", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}}
{"id": "moa.assertion:179", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Two patients with metastatic colorectal neuroendocrine tumors refractory to treatment exhibited a durable response to combined BRAF-MEK inhibition. One patient with BRAF V600E observed ongoing response lasting over 7 months when treated with dabrafenib and trametinib in combination.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:75", "type": "Document", "label": "Klempner SJ, Gershenhorn B, Tran P, et al. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov. 2016;6(6):594-600.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/2159-8290.CD-15-1192"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27048246", "doi:10.1158/2159-8290.CD-15-1192"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:6CyoTugChKpK_-JBLr3OxgECTwq1t3he", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "oncotree:HGNEC", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AHGNEC", "type": "DiseaseDescriptor", "label": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum", "xrefs": ["oncotree:HGNEC"], "disease": "oncotree:HGNEC"}, "object_descriptor": {"id": "moa.tcd:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Dabrafenib", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1424911"}, {"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}]}}
{"id": "moa.assertion:180", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Two patients with metastatic colorectal neuroendocrine tumors refractory to treatment exhibited a durable response to combined BRAF-MEK inhibition. One patient with BRAF V600E observed ongoing response lasting 9 months when treated with vemurafenib and trametinib in combination.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:75", "type": "Document", "label": "Klempner SJ, Gershenhorn B, Tran P, et al. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov. 2016;6(6):594-600.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/2159-8290.CD-15-1192"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27048246", "doi:10.1158/2159-8290.CD-15-1192"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:wtQAZ9txM3dle1_okKdQ8NP96mIPILLX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "oncotree:HGNEC", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AHGNEC", "type": "DiseaseDescriptor", "label": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum", "xrefs": ["oncotree:HGNEC"], "disease": "oncotree:HGNEC"}, "object_descriptor": {"id": "moa.tcd:xQv-2m99rVOprssTMAjOqFqgoYXQuioO", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}, {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}]}}
{"id": "moa.assertion:181", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical evidence suggests the combination of proteasome inhibitor ixazomib with interferon-alpha may negatively impact tumor cell viability in melanoma, particularly in patients with BRAF V600E mutations.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:76", "type": "Document", "label": "Suarez-kelly LP, Kemper GM, Duggan MC, et al. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget. 2016;", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.18632/oncotarget.12791"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27783987", "doi:10.18632/oncotarget.12791"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:IGebrRi3pBZT6tVnLAijFiE42SGtWwhT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C2220", "type": "Therapeutic"}, {"id": "rxcui:1723735", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.tcd:NmGaX2IchyPJJ5hrP9xxsLPbTPlUBTWc", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C2220", "type": "Therapeutic"}, {"id": "rxcui:1723735", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Interferon-alpha", "type": "TherapeuticDescriptor", "label": "Interferon-alpha", "therapeutic": "ncit:C2220"}, {"id": "moa.normalize.therapy:Ixazomib", "type": "TherapeuticDescriptor", "label": "Ixazomib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1723735"}]}}
{"id": "moa.assertion:188", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "BRAF V600E mutations were associated with sensitivity to the BRAF inhibitor PLX-4032 in a study of 109 microdissected pancreatic ductal adenocarcinoma patients.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:52", "type": "Document", "label": "Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1038/ncomms7744"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:25855536", "doi:10.1038/ncomms7744"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:v39cAkaFusP-jLe-o2tnp6s14gwtmkkL", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C8294", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3APAAD", "type": "DiseaseDescriptor", "label": "Pancreatic Adenocarcinoma", "xrefs": ["oncotree:PAAD"], "disease": "ncit:C8294"}, "object_descriptor": {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}}
{"id": "moa.assertion:189", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Vemurafenib monotherapy is efficacious in preclinical models of pediatric gliomas harboring BRAF V600E mutations, but resistance quickly develops. EGFR inhibition appears to rescue the effects of vemurafenib in these models.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:79", "type": "Document", "label": "Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015;6(26):21993-2005.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.18632/oncotarget.4014"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:26023796", "doi:10.18632/oncotarget.4014"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:_zze4Y1ZLV7euqsZRhUzDVPC9icrSngU", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "oncotree:GNOS", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AGNOS", "type": "DiseaseDescriptor", "label": "Glioma", "xrefs": ["oncotree:GNOS"], "disease": "oncotree:GNOS"}, "object_descriptor": {"id": "moa.tcd:0trcUgfHzHFLIvacsRpjWHnI1eN8XvQc", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Neratinib", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1940643"}, {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}]}}
{"id": "moa.assertion:190", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:64", "type": "Document", "label": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:GVWLaUTvooisOCN4vC0rlsMIvjfn6SGs", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C5105", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACOADREAD", "type": "DiseaseDescriptor", "label": "Colorectal Adenocarcinoma", "xrefs": ["oncotree:COADREAD"], "disease": "ncit:C5105"}, "object_descriptor": {"id": "moa.normalize.therapy:Cetuximab", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "therapeutic": "rxcui:318341"}}
{"id": "moa.assertion:192", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Vemurafenib alone had insufficient activity in BRAF V600E mutant colorectal cancer patients. Of patients who received vemurafenib and cetuximab, one response was observed; however, approximately half of the patients had tumor regression that did not meet the standard criteria of partial response.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:73", "type": "Document", "label": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1056/NEJMoa1502309"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:26287849", "doi:10.1056/NEJMoa1502309", "nct:NCT01524978"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:R3CE5nrwjba7UhAqS2LM5vM2BBfpLvM7", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C5105", "type": "Disease"}}, "subject_descriptor": "moa.variant:149", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACOADREAD", "type": "DiseaseDescriptor", "label": "Colorectal Adenocarcinoma", "xrefs": ["oncotree:COADREAD"], "disease": "ncit:C5105"}, "object_descriptor": {"id": "moa.tcd:Xu3LpnoQkk74JyWy2b90_Y6KSgb4Gdst", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Cetuximab", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "therapeutic": "rxcui:318341"}, {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}]}}
{"id": "moa.assertion:254", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:90", "type": "Document", "label": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:NscnHk0pW34_5hMmk1-FmvCOlH71QsXE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:254", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Osimertinib", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1721560"}}
{"id": "moa.assertion:257", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:91", "type": "Document", "label": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:ubBKghiT5mGCQMsup4qNdWzTBY-OMFzG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:254", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Gefitinib", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:328134"}}
{"id": "moa.assertion:261", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Durvalumab (a PD-L1 inhibitor), is being evaluated in combination with Osimertinib (an EGFR-TKI) in patients with sensitizing EGFR mutations or T790M.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:92", "type": "Document", "label": "Ahn MJ, Yang J, Yu H, et al. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. J Thorac Oncol. 2016;11(4 Suppl):S115.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1016/S1556-0864(16)30246-5"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27599705", "doi:10.1016/S1556-0864(16)30246-5", "nct:NCT02143466"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:gBZjWmHbY5xc_WGbjvlcZZxa8YKOkXbW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1919503", "type": "Therapeutic"}, {"id": "rxcui:1721560", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:254", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.tcd:9vUH8jAN_UCLGblx4LtQdsL8c_EHtvE_", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Combination therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1919503", "type": "Therapeutic"}, {"id": "rxcui:1721560", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Durvalumab", "type": "TherapeuticDescriptor", "label": "Durvalumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D008175", "type": "DiseaseDescriptor", "label": "Lung Neoplasms", "disease": "ncit:C3200"}, {"id": "mesh:D055752", "type": "DiseaseDescriptor", "label": "Small Cell Lung Carcinoma", "disease": "ncit:C4917"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D002289", "type": "DiseaseDescriptor", "label": "Carcinoma, Non-Small-Cell Lung", "disease": "ncit:C2926"}, {"id": "mesh:D001749", "type": "DiseaseDescriptor", "label": "Urinary Bladder Neoplasms", "disease": "ncit:C9334"}]}}], "therapeutic": "rxcui:1919503"}, {"id": "moa.normalize.therapy:Osimertinib", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1721560"}]}}
{"id": "moa.assertion:263", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "HM61713 showed clinical activity in patients with an EGFR T790M mutation in a Phase I trial.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:94", "type": "Document", "label": "Park K, Lee J, Han J, et al. 1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose Journal of Thoracic Oncology. 2016; 11(4):S113-.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1016/S1556-0864(16)30243-X"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["doi:10.1016/S1556-0864(16)30243-X", "nct:NCT01588145"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:MMku2ZhHoQBa_n1yv1jbQnIuqYI5KS9j", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C101791", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:254", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Olmutinib", "type": "TherapeuticDescriptor", "label": "Olmutinib", "therapeutic": "ncit:C101791"}}
{"id": "moa.assertion:267", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Dacomitinib is being evaluated in comparison with gefitinib for the treatment of locally advanced or metastatic non-small cell lung cancer.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:98", "type": "Document", "label": "Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1016/j.tips.2016903"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27717507", "doi:10.1016/j.tips.2016903", "nct:NCT01774721"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:p7sVbOSDxfEcJfJzPqC8Kxl7rO37GPxZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2058848", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:267", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Dacomitinib", "type": "TherapeuticDescriptor", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:2058848"}}
{"id": "moa.assertion:269", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Osimertinib is being evaluated in patients who have progressed following treatment with an EGFR TKI.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:100", "type": "Document", "label": "Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1016/j.tips.2016903"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27717507", "doi:10.1016/j.tips.2016903", "nct:NCT02094261"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:NscnHk0pW34_5hMmk1-FmvCOlH71QsXE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:254", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Osimertinib", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1721560"}}
{"id": "moa.assertion:270", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Rociletinib was found to be effective in some patients in a 130-patient trial.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:101", "type": "Document", "label": "Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700-9.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1056/NEJMoa1413654"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:25923550", "doi:10.1056/NEJMoa1413654", "nct:NCT01526928"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:UDP5UTYpeIjYWI3Cf3W4EflMGFKZ3L9J", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C99905", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:254", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Rociletinib", "type": "TherapeuticDescriptor", "label": "Rociletinib", "therapeutic": "ncit:C99905"}}
{"id": "moa.assertion:272", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Osimertinib is FDA-Approved for metastatic non-small cell lung cancer patients with EGFR T790M mutations.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:103", "type": "Document", "label": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1186/s13045-016-0268-z"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27071706", "doi:10.1186/s13045-016-0268-z"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:NscnHk0pW34_5hMmk1-FmvCOlH71QsXE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:254", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Osimertinib", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1721560"}}
{"id": "moa.assertion:273", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:103", "type": "Document", "label": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1186/s13045-016-0268-z"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27071706", "doi:10.1186/s13045-016-0268-z"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:T9jWh-bqNKcCYc703WTmkIHFJOcnNCCY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C115109", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:267", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:EGF816", "type": "TherapeuticDescriptor", "label": "EGF816", "therapeutic": "ncit:C115109"}}
{"id": "moa.assertion:274", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:103", "type": "Document", "label": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1186/s13045-016-0268-z"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27071706", "doi:10.1186/s13045-016-0268-z"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:7kJjVZ_qeMyIWvwD_wfSHHvMJ4acmjD5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C115109", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:254", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:EGF816", "type": "TherapeuticDescriptor", "label": "EGF816", "therapeutic": "ncit:C115109"}}
{"id": "moa.assertion:275", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:103", "type": "Document", "label": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1186/s13045-016-0268-z"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27071706", "doi:10.1186/s13045-016-0268-z"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:oxBV40AufrTYPDYEfVefvC54B2drmlzA", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C120307", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:267", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:PF-06747775", "type": "TherapeuticDescriptor", "label": "PF-06747775", "therapeutic": "ncit:C120307"}}
{"id": "moa.assertion:276", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:103", "type": "Document", "label": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1186/s13045-016-0268-z"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:27071706", "doi:10.1186/s13045-016-0268-z"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:1EODaROcJraDNQZJvsll5e7EYZUEJETu", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C120307", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:254", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:PF-06747775", "type": "TherapeuticDescriptor", "label": "PF-06747775", "therapeutic": "ncit:C120307"}}
{"id": "moa.assertion:277", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "TKI therapy for patients with T790M has limited benefit.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:104", "type": "Document", "label": "Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing Annals of Oncology. 2014; 25(2):423-428.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1093/annonc/mdt573"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:24478319", "doi:10.1093/annonc/mdt573"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:DBx_D7JPPPE0dTTK1bfQDhyUMNPebSvz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:254", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Erlotinib", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "therapeutic": "rxcui:337525"}}
{"id": "moa.assertion:278", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "TKI therapy for patients with T790M has limited benefit.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:104", "type": "Document", "label": "Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing Annals of Oncology. 2014; 25(2):423-428.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1093/annonc/mdt573"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:24478319", "doi:10.1093/annonc/mdt573"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:Cjf96A9wqWIQMgUTz28OTg6JDrFqFPnQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:254", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Afatinib", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "therapeutic": "rxcui:1430438"}}
{"id": "moa.assertion:281", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:105", "type": "Document", "label": "Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:AEC2fbyX0a0Y3wtOYoALtu06a2AJbVtm", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:267", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Afatinib", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "therapeutic": "rxcui:1430438"}}
{"id": "moa.assertion:284", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 3 trial, EGFR mutant positive advanced NSCLC (n=556) patients observed significantly longer PFS when treated with osimertinib instead of standard EGFR-TKIs.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:107", "type": "Document", "label": "Soria J, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated -Mutated Advanced Non-Small-Cell Lung Cancer N Engl J Med. 2018; 378(2):113-125.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1056/NEJMoa1713137"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:29151359", "doi:10.1056/NEJMoa1713137"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:btf_YXh-Xokf9PrBB-GipkFRbcngQGZZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:284", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Osimertinib", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1721560"}}
{"id": "moa.assertion:286", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 21 L858R mutations, as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:108", "type": "Document", "label": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf. Revised December 2020. Accessed February 2nd, 2021.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:btf_YXh-Xokf9PrBB-GipkFRbcngQGZZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:286", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Osimertinib", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:1721560"}}
{"id": "moa.assertion:294", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:23", "type": "Document", "label": "Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1371/journal.pgen.1004135"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:24550739", "doi:10.1371/journal.pgen.1004135"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:nbsvz_VlZa_aCuk17ti7Vs4llMQpomcW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.yI-Frf1V6gEML12FtvK6iHuTF1EX6seG", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4436", "type": "Disease"}}, "subject_descriptor": "moa.variant:294", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACHOL", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "xrefs": ["oncotree:CHOL"], "disease": "ncit:C4436"}, "object_descriptor": {"id": "moa.normalize.therapy:Erlotinib", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "therapeutic": "rxcui:337525"}}
{"id": "moa.assertion:300", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:115", "type": "Document", "label": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:RFqdXdSsF3nD2V-odL_nei4Bf2c5w0U1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.A5YxtqhWagumyhO969Gimt_M_PfgcagW", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2274378", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3209", "type": "Disease"}}, "subject_descriptor": "moa.variant:300", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AFL", "type": "DiseaseDescriptor", "label": "Follicular Lymphoma", "xrefs": ["oncotree:FL"], "disease": "ncit:C3209"}, "object_descriptor": {"id": "moa.normalize.therapy:Tazemetostat", "type": "TherapeuticDescriptor", "label": "Tazemetostat", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": []}}], "therapeutic": "rxcui:2274378"}}
{"id": "moa.assertion:301", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:115", "type": "Document", "label": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:Tq1tCF6KCVVIK9HzbzXXXf4dGZRHzkKm", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ynbfjaaWCYBksQZrVVRaOxnJbpA9DbVM", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2274378", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3209", "type": "Disease"}}, "subject_descriptor": "moa.variant:301", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AFL", "type": "DiseaseDescriptor", "label": "Follicular Lymphoma", "xrefs": ["oncotree:FL"], "disease": "ncit:C3209"}, "object_descriptor": {"id": "moa.normalize.therapy:Tazemetostat", "type": "TherapeuticDescriptor", "label": "Tazemetostat", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": []}}], "therapeutic": "rxcui:2274378"}}
{"id": "moa.assertion:302", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:115", "type": "Document", "label": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:ffUYVaYwvp7gc2KAADQUaxm6mXfAV9O9", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CratvFcQXEfAaLsrwtDErLAtt479jNPI", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2274378", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3209", "type": "Disease"}}, "subject_descriptor": "moa.variant:302", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AFL", "type": "DiseaseDescriptor", "label": "Follicular Lymphoma", "xrefs": ["oncotree:FL"], "disease": "ncit:C3209"}, "object_descriptor": {"id": "moa.normalize.therapy:Tazemetostat", "type": "TherapeuticDescriptor", "label": "Tazemetostat", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": []}}], "therapeutic": "rxcui:2274378"}}
{"id": "moa.assertion:303", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:115", "type": "Document", "label": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:J1lrJV-uUqqor4GNyc4-zBJcSMEzOQLc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.MbvGD_JLAgpChHv3szojqtKfyjVZ8UOM", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2274378", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3209", "type": "Disease"}}, "subject_descriptor": "moa.variant:303", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AFL", "type": "DiseaseDescriptor", "label": "Follicular Lymphoma", "xrefs": ["oncotree:FL"], "disease": "ncit:C3209"}, "object_descriptor": {"id": "moa.normalize.therapy:Tazemetostat", "type": "TherapeuticDescriptor", "label": "Tazemetostat", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": []}}], "therapeutic": "rxcui:2274378"}}
{"id": "moa.assertion:304", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:115", "type": "Document", "label": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:PnfZOVIoeLCEhuWHxtgJ2A5wUmAeoPpy", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.xVJJc3REms4TVqq1F2ed3fgwM0j70avb", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2274378", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3209", "type": "Disease"}}, "subject_descriptor": "moa.variant:304", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AFL", "type": "DiseaseDescriptor", "label": "Follicular Lymphoma", "xrefs": ["oncotree:FL"], "disease": "ncit:C3209"}, "object_descriptor": {"id": "moa.normalize.therapy:Tazemetostat", "type": "TherapeuticDescriptor", "label": "Tazemetostat", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": []}}], "therapeutic": "rxcui:2274378"}}
{"id": "moa.assertion:307", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:27", "type": "Document", "label": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:KlQ1wUHsq7yMvDBq8_er-ru_eeghpJic", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.X0Qffarg2hsUJnsCo8lJ2bBo_d_AI2PS", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2123125", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C39851", "type": "Disease"}}, "subject_descriptor": "moa.variant:307", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABLCA", "type": "DiseaseDescriptor", "label": "Bladder Urothelial Carcinoma", "xrefs": ["oncotree:BLCA"], "disease": "ncit:C39851"}, "object_descriptor": {"id": "moa.normalize.therapy:Erdafitinib", "type": "TherapeuticDescriptor", "label": "Erdafitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}]}}], "therapeutic": "rxcui:2123125"}}
{"id": "moa.assertion:308", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:27", "type": "Document", "label": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:K97abpg-YUKXlPj-VAPdHaQ7a5xIdVYw", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.FNHAUxkAFnYKIjkp3qxbDsoN31F2i-wp", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2123125", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C39851", "type": "Disease"}}, "subject_descriptor": "moa.variant:308", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABLCA", "type": "DiseaseDescriptor", "label": "Bladder Urothelial Carcinoma", "xrefs": ["oncotree:BLCA"], "disease": "ncit:C39851"}, "object_descriptor": {"id": "moa.normalize.therapy:Erdafitinib", "type": "TherapeuticDescriptor", "label": "Erdafitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}]}}], "therapeutic": "rxcui:2123125"}}
{"id": "moa.assertion:309", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:27", "type": "Document", "label": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:T6NwDHhAJdQnA7K71RiCoU2qar5yF-Oz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.-u7UUrAjLYvs-n8V1rUNw4hAoHaFZyAR", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2123125", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C39851", "type": "Disease"}}, "subject_descriptor": "moa.variant:309", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABLCA", "type": "DiseaseDescriptor", "label": "Bladder Urothelial Carcinoma", "xrefs": ["oncotree:BLCA"], "disease": "ncit:C39851"}, "object_descriptor": {"id": "moa.normalize.therapy:Erdafitinib", "type": "TherapeuticDescriptor", "label": "Erdafitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}]}}], "therapeutic": "rxcui:2123125"}}
{"id": "moa.assertion:310", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:27", "type": "Document", "label": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:7ZnJMj963LEbLPNJU44ENQk-JUcypn7i", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G1B7U93AVZ0qmmd6CkAFL5JgaU43EdRP", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2123125", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C39851", "type": "Disease"}}, "subject_descriptor": "moa.variant:310", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABLCA", "type": "DiseaseDescriptor", "label": "Bladder Urothelial Carcinoma", "xrefs": ["oncotree:BLCA"], "disease": "ncit:C39851"}, "object_descriptor": {"id": "moa.normalize.therapy:Erdafitinib", "type": "TherapeuticDescriptor", "label": "Erdafitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}]}}], "therapeutic": "rxcui:2123125"}}
{"id": "moa.assertion:317", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:119", "type": "Document", "label": "Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1038/leu.2013.14"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:23392356", "doi:10.1038/leu.2013.14"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:5ZUI8pVBxocNseMu5B9XHgmAU8W0USL1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.alBmNUrND2Qcobv2zz7socu-8G727NX9", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C68936", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "subject_descriptor": "moa.variant:317", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AAML", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["oncotree:AML"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "moa.normalize.therapy:Quizartinib", "type": "TherapeuticDescriptor", "label": "Quizartinib", "therapeutic": "ncit:C68936"}}
{"id": "moa.assertion:318", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:120", "type": "Document", "label": "Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1038/sj.leu.2404374"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:16990784", "doi:10.1038/sj.leu.2404374"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:CkfI-Svkig14C0_D5QRuYjtLxwZaBQ6p", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.42RunKCk9_3PSfdTBKEVee7vT9Zkn4XP", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "subject_descriptor": "moa.variant:318", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AAML", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["oncotree:AML"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "moa.normalize.therapy:Sunitinib", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "therapeutic": "rxcui:357977"}}
{"id": "moa.assertion:319", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:121", "type": "Document", "label": "Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1038/nature11143"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:22722193", "doi:10.1038/nature11143"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:6VXOnpzE8PWFpqCMNYsl-kL0bID_JNi1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.13xXRZQ1mZltR6vaTb6XrSRPHkIOu1vt", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:72965", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:319", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Letrozole", "type": "TherapeuticDescriptor", "label": "Letrozole", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "therapeutic": "rxcui:72965"}}
{"id": "moa.assertion:323", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:125", "type": "Document", "label": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf. Revised August 2021. Accessed September 2nd, 2021.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:JiKWgplj0PQYD0joZkhJM_C8fTKZ2ZyY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cXxt95ehS1vnyR-ZKhMNpx2eKUX136uo", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2049873", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "subject_descriptor": "moa.variant:323", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AAML", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["oncotree:AML"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "moa.normalize.therapy:Ivosidenib", "type": "TherapeuticDescriptor", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "disease": "ncit:C4436"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "therapeutic": "rxcui:2049873"}}
{"id": "moa.assertion:324", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:125", "type": "Document", "label": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf. Revised August 2021. Accessed September 2nd, 2021.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:XzhdxvwlwRCnwF5SATQDFHseoCCFLXYL", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rNhxmp_gYSRocQWOzkt83kNujGnV-BVj", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2049873", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "subject_descriptor": "moa.variant:324", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AAML", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["oncotree:AML"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "moa.normalize.therapy:Ivosidenib", "type": "TherapeuticDescriptor", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "disease": "ncit:C4436"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "therapeutic": "rxcui:2049873"}}
{"id": "moa.assertion:325", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:125", "type": "Document", "label": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf. Revised August 2021. Accessed September 2nd, 2021.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:O3B7QaqYLl2prolEOW8YQU_dMVsH3g97", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cXxt95ehS1vnyR-ZKhMNpx2eKUX136uo", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2049873", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4436", "type": "Disease"}}, "subject_descriptor": "moa.variant:323", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACHOL", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "xrefs": ["oncotree:CHOL"], "disease": "ncit:C4436"}, "object_descriptor": {"id": "moa.normalize.therapy:Ivosidenib", "type": "TherapeuticDescriptor", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "disease": "ncit:C4436"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "therapeutic": "rxcui:2049873"}}
{"id": "moa.assertion:326", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:125", "type": "Document", "label": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf. Revised August 2021. Accessed September 2nd, 2021.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:5lo8Q4sBfsUs--bldiQncuNgBzTYB_X1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rNhxmp_gYSRocQWOzkt83kNujGnV-BVj", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2049873", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4436", "type": "Disease"}}, "subject_descriptor": "moa.variant:324", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ACHOL", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "xrefs": ["oncotree:CHOL"], "disease": "ncit:C4436"}, "object_descriptor": {"id": "moa.normalize.therapy:Ivosidenib", "type": "TherapeuticDescriptor", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "disease": "ncit:C4436"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "therapeutic": "rxcui:2049873"}}
{"id": "moa.assertion:329", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:126", "type": "Document", "label": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}], "xrefs": ["nct:NCT01915498"]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:HQvXtsoKlajmb6YZ9aovtlRUWds6UamR", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SUyY1Hguz5PVWM_vB1tVzkh-8ui55NlU", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940332", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "subject_descriptor": "moa.variant:329", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AAML", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["oncotree:AML"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "moa.normalize.therapy:Enasidenib", "type": "TherapeuticDescriptor", "label": "Enasidenib", "therapeutic": "rxcui:1940332"}}
{"id": "moa.assertion:330", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:126", "type": "Document", "label": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}], "xrefs": ["nct:NCT01915498"]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:kap-LS13PZwie6dw973TN0wbv7x1LzcX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.xMJo2AO4MxjhpniTGhf9fVOqtxNO1mjR", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940332", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "subject_descriptor": "moa.variant:330", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AAML", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["oncotree:AML"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "moa.normalize.therapy:Enasidenib", "type": "TherapeuticDescriptor", "label": "Enasidenib", "therapeutic": "rxcui:1940332"}}
{"id": "moa.assertion:331", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:126", "type": "Document", "label": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}], "xrefs": ["nct:NCT01915498"]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:aRmyRPMsIeVOSbUDRNhd0wtNLp7EJXay", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.goBOnCF2dK5HRyMb2AqYW0Xd6RGGsz4N", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940332", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "subject_descriptor": "moa.variant:331", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AAML", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["oncotree:AML"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "moa.normalize.therapy:Enasidenib", "type": "TherapeuticDescriptor", "label": "Enasidenib", "therapeutic": "rxcui:1940332"}}
{"id": "moa.assertion:338", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:128", "type": "Document", "label": "Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2015-03-635821"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:26443624", "doi:10.1182/blood-2015-03-635821"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:9MazqU-6_lH4crqJMlUqnQaBnl63vLjf", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Y1yYokD6lgVPrzzpcyVyYBFb-_nT_ZTa", "predicate": "predicts_sensitivity_to", "object": {"id": "drugbank:DB12638", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3167", "type": "Disease"}}, "subject_descriptor": "moa.variant:338", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:Acute%20Lymphoid%20Leukemia", "type": "DiseaseDescriptor", "label": "Acute Lymphoid Leukemia", "xrefs": ["oncotree:ALL"], "disease": "ncit:C3167"}, "object_descriptor": {"id": "moa.normalize.therapy:PU-H71", "type": "TherapeuticDescriptor", "label": "PU-H71", "therapeutic": "drugbank:DB12638"}}
{"id": "moa.assertion:339", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MOHITO JAK1 A634D transplated mice were highly sensitive to growth inhibition by PU-H71.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:128", "type": "Document", "label": "Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1182/blood-2015-03-635821"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:26443624", "doi:10.1182/blood-2015-03-635821"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:2xfTyM6zuVjneVDvAdRK1cWKtOEiixtT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4pF-TNpYtJUV0AHyShNxiZKpC7YEShTl", "predicate": "predicts_sensitivity_to", "object": {"id": "drugbank:DB12638", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3167", "type": "Disease"}}, "subject_descriptor": "moa.variant:339", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:Acute%20Lymphoid%20Leukemia", "type": "DiseaseDescriptor", "label": "Acute Lymphoid Leukemia", "xrefs": ["oncotree:ALL"], "disease": "ncit:C3167"}, "object_descriptor": {"id": "moa.normalize.therapy:PU-H71", "type": "TherapeuticDescriptor", "label": "PU-H71", "therapeutic": "drugbank:DB12638"}}
{"id": "moa.assertion:352", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:131", "type": "Document", "label": "Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:4QYVPy5FKvofBF5kngojgMez4eKlTdoQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.i9jXgMZM9ZFX7HMNEDN7npl5Cl5zSgy6", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "subject_descriptor": "moa.variant:352", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AGIST", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["oncotree:GIST"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "moa.normalize.therapy:Regorafenib", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "therapeutic": "rxcui:1312397"}}
{"id": "moa.assertion:353", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:131", "type": "Document", "label": "Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:Rrmqd2v61L9z4q5qcfyhXqyD2Ig_gyn2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CW1xXH97SiVFOHQp0rQ7-T5yYdwCE3ta", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "subject_descriptor": "moa.variant:353", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AGIST", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["oncotree:GIST"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "moa.normalize.therapy:Regorafenib", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "therapeutic": "rxcui:1312397"}}
{"id": "moa.assertion:355", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:132", "type": "Document", "label": "Pfizer, Inc. Sutent (sunitinib malate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:o9qdKyAqWA2cwYHD3Y3Pdul9NsZmPXJF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.i9jXgMZM9ZFX7HMNEDN7npl5Cl5zSgy6", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "subject_descriptor": "moa.variant:352", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AGIST", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["oncotree:GIST"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "moa.normalize.therapy:Sunitinib", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "therapeutic": "rxcui:357977"}}
{"id": "moa.assertion:356", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:132", "type": "Document", "label": "Pfizer, Inc. Sutent (sunitinib malate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:XOC3psUflO_k0P7NI7IYLM7Plz_e7NmP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CW1xXH97SiVFOHQp0rQ7-T5yYdwCE3ta", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "subject_descriptor": "moa.variant:353", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AGIST", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["oncotree:GIST"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "moa.normalize.therapy:Sunitinib", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "therapeutic": "rxcui:357977"}}
{"id": "moa.assertion:361", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:134", "type": "Document", "label": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:K8Nu4XG5BuzSHQ1x-QoJHhpcJgylzH-P", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RSdgYrnskYJsisVrHJ26ILyUNVaMqod2", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:361", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Imatinib", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "therapeutic": "rxcui:282388"}}
{"id": "moa.assertion:362", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:134", "type": "Document", "label": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:2QMGgO5RDtf1nRZmK6bk-PQatXAbwliU", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.PrsYP_F6Rj3Tj625OyLOTEFSItWy6WrZ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:362", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Imatinib", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "therapeutic": "rxcui:282388"}}
{"id": "moa.assertion:363", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:134", "type": "Document", "label": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:i6TguPECrigAWShU76ltDXTzAdQY5HId", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.BaZWPlKu4TH25oZATbLEUf5p4VvfpVH2", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:363", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Imatinib", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "therapeutic": "rxcui:282388"}}
{"id": "moa.assertion:364", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:134", "type": "Document", "label": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:LqnAPUHyLFUwofipT2eoevnkT11VDlNs", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Lb_d6ANJs93uDVVlJujz1_7iA4-VggYu", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:364", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Imatinib", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "therapeutic": "rxcui:282388"}}
{"id": "moa.assertion:365", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:134", "type": "Document", "label": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:rkHNxDuZE6gxoXuwOQs3eGahrDkam59a", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jD9f-R_toWrduybrjbm68lsaOpntmZAa", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:365", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Imatinib", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "therapeutic": "rxcui:282388"}}
{"id": "moa.assertion:366", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:134", "type": "Document", "label": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:J_sn-SwRIpXGfOSEifQzItnAmrt0B4DU", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.1i40nlLTUTxkw3VAG3tTQSuNjTWnMdy5", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:366", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Imatinib", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "therapeutic": "rxcui:282388"}}
{"id": "moa.assertion:367", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:134", "type": "Document", "label": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}, {"type": "Extension", "name": "source_type", "value": "Guideline"}]}], "evidence_level": {"id": "vicc:e00003", "type": "Coding", "label": "professional guideline evidence"}, "target_proposition": {"id": "proposition:nTfiznZy85PSXNppSoc33gqCzM4R9iMc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.qqyXsR4-bT1oCgmCJM4qHholRwDQ602L", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:367", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Imatinib", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "therapeutic": "rxcui:282388"}}
{"id": "moa.assertion:374", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Avapritnib inhibited the autophosphorylation of KIT p.D816V in cellular assays relative to wild-type KIT.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:137", "type": "Document", "label": "Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf. Accessed September 2nd, 2021.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:mfKw17ecEgmPFKCeptpB4jTiKklgGI2b", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nMt7siwiRwJd_T_l46fg_fFaPZ7-H4sN", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2272107", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "subject_descriptor": "moa.variant:374", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AGIST", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["oncotree:GIST"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "moa.normalize.therapy:Avapritinib", "type": "TherapeuticDescriptor", "label": "Avapritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2272107"}}
{"id": "moa.assertion:387", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sotorasib, a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:141", "type": "Document", "label": "Amgen Inc. Lumakras (sotorasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:ZTdOTP2yGpurS9-SQJQrevVbsEA2CUkj", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2550714", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:387", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Sotorasib", "type": "TherapeuticDescriptor", "label": "Sotorasib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:2550714"}}
{"id": "moa.assertion:388", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:142", "type": "Document", "label": "J Clin Oncol 37, 2019 (suppl; abstr 3003)", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://abstracts.asco.org/239/AbstView_239_268371.html"}, {"type": "Extension", "name": "source_type", "value": "Abstract"}], "xrefs": ["nct:NCT03600883"]}], "evidence_level": {"id": "vicc:e00006", "type": "Coding", "label": "interventional study evidence"}, "target_proposition": {"id": "proposition:ZTdOTP2yGpurS9-SQJQrevVbsEA2CUkj", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2550714", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:387", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:AMG%20510", "type": "TherapeuticDescriptor", "label": "AMG 510", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:2550714"}}
{"id": "moa.assertion:402", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:70", "type": "Document", "label": "Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1073/pnas905833106"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:19915144", "doi:10.1073/pnas905833106"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:L8p0XTRDF9wIedy3khyXrARpRdQY1ftA", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gMoA6xM6UlrtLm_mVKKbU2FFZVR15lzr", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:402", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}}
{"id": "moa.assertion:403", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:70", "type": "Document", "label": "Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1073/pnas905833106"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:19915144", "doi:10.1073/pnas905833106"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:-Jj0XA1DscT_R_PJR-rUhw7NzM2mfZPt", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.irDnXyyR0inhcZ38LFSzr4sIb6e2Lx7s", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:403", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}}
{"id": "moa.assertion:404", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest resistance to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:70", "type": "Document", "label": "Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1073/pnas905833106"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:19915144", "doi:10.1073/pnas905833106"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:mPI9TCc5YxxyXUFMT3e1IfwR-JaRfsUQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gMoA6xM6UlrtLm_mVKKbU2FFZVR15lzr", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:402", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:405", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:150", "type": "Document", "label": "Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/0008-5472.CAN-08-0099"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18632602", "doi:10.1158/0008-5472.CAN-08-0099"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:KbPCmxKq2zGobdXTExi1wwU3TxBE_YgW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.irDnXyyR0inhcZ38LFSzr4sIb6e2Lx7s", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "subject_descriptor": "moa.variant:403", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ANSCLC", "type": "DiseaseDescriptor", "label": "Non-Small Cell Lung Cancer", "xrefs": ["oncotree:NSCLC"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:406", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MEK1 Q56P confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:151", "type": "Document", "label": "Trunzer, Kerstin, et al. \"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.\" Journal of Clinical Oncology 31.14 (2013): 1767-1774.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2012.44.7888"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:23569304", "doi:10.1200/JCO.2012.44.7888"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:-Jj0XA1DscT_R_PJR-rUhw7NzM2mfZPt", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.irDnXyyR0inhcZ38LFSzr4sIb6e2Lx7s", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:403", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}}
{"id": "moa.assertion:407", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MEK1 Q56P confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:151", "type": "Document", "label": "Trunzer, Kerstin, et al. \"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.\" Journal of Clinical Oncology 31.14 (2013): 1767-1774.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2012.44.7888"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:23569304", "doi:10.1200/JCO.2012.44.7888"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1aPcU7TMa9lfeFBY_Mugg7ujbDGqtk56", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.irDnXyyR0inhcZ38LFSzr4sIb6e2Lx7s", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:403", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:408", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MEK1 C121S confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:152", "type": "Document", "label": "Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2010.33.2312"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:21383288", "doi:10.1200/JCO.2010.33.2312"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:a0Te09vtxFhjZyPzoNvzjxKgOzajrZa2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.UzMvDxAVEEQbq31meAbiBkIvleY7w-ke", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:408", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Vemurafenib", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "therapeutic": "rxcui:1147220"}}
{"id": "moa.assertion:409", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MEK1 C121S confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:152", "type": "Document", "label": "Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2010.33.2312"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:21383288", "doi:10.1200/JCO.2010.33.2312"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ZzVFcNsX-nwTvAwWRhM3kcBO8k_pueWp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.UzMvDxAVEEQbq31meAbiBkIvleY7w-ke", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:408", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:410", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:78", "type": "Document", "label": "Wagle, Nikhil, et al. \"MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.\" Cancer discovery 4.1 (2014): 61-68.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/2159-8290.CD-13-0631"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:24265154", "doi:10.1158/2159-8290.CD-13-0631"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:ZJ5NtXMx0yiExA1q5y-wTOrNQZZ9CV1i", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.JXOJDjpsROlaBJohocLPg6A3ZwC7ofZ5", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1425098", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:410", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Trametinib", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "therapeutic": "rxcui:1425098"}}
{"id": "moa.assertion:411", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:153", "type": "Document", "label": "Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1001/jamaoncol.2015.34"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:26181029", "doi:10.1001/jamaoncol.2015.34"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:7VAZDJhBQ8v-ALVRFzrFs4RJxwmG74w1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.401wL6hOe-0nralm6dqE6-jiulch3DcC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C34447", "type": "Disease"}}, "subject_descriptor": "moa.variant:411", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AHNSC", "type": "DiseaseDescriptor", "label": "Head and Neck Squamous Cell Carcinoma", "xrefs": ["oncotree:HNSC"], "disease": "ncit:C34447"}, "object_descriptor": {"id": "moa.normalize.therapy:Erlotinib", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "therapeutic": "rxcui:337525"}}
{"id": "moa.assertion:413", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to SU11274.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:155", "type": "Document", "label": "Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/0008-5472.CAN-08-2881"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:19318576", "doi:10.1158/0008-5472.CAN-08-2881"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:HVAKlChn6Zwa7lxBYscqm8vKARzQ4i5j", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.uQhgRqg5AvenJJFEF4zkS6FhVYBwBGQr", "predicate": "predicts_sensitivity_to", "object": {"id": "iuphar.ligand:5057", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C34447", "type": "Disease"}}, "subject_descriptor": "moa.variant:413", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AHNSC", "type": "DiseaseDescriptor", "label": "Head and Neck Squamous Cell Carcinoma", "xrefs": ["oncotree:HNSC"], "disease": "ncit:C34447"}, "object_descriptor": {"id": "moa.normalize.therapy:SU11274", "type": "TherapeuticDescriptor", "label": "SU11274", "therapeutic": "iuphar.ligand:5057"}}
{"id": "moa.assertion:432", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:MJ-CxEl5Xwf3H5MzUu4NyqXe9lDSc9e1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.e2B_sheTrWVhFEn7FqNH0SsIYqSIZYw7", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:432", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:433", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:-zTxp1xkQAOMDivazOp3bugwLXvYMdYg", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.92FRkuJwxvJq_ofcr84NmLCFyJApDGMu", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:433", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:434", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:IixJB-r6Si8sRudi5Cz-RCd-tY5w1x-K", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Om0yyht6SnNmdAVYgTuYIXptr3aYzSx5", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:434", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:435", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:d-Q6xoWOV68rtHXnePXMqtknvXdM0b9k", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.W2nm3lhDKPQQ2DWtoonlKqtfc4CJykOZ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:435", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:436", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:qLIdLjzUZUmcOWgTL6GU8ZJkxW4y9WIz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.becYTmv4zDcIlE2ZTxGGrPRVur9w6T79", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:436", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:437", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:ej0sKRWLdL205Fcc-UpDX8GVWGfLvjYv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.T0mmdfyaSGcV0308PZS2AXvptIbN3UYq", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:437", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:438", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:UeKjYOmoOJQZC06256aKmcrAoQvT1VJ9", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.qfpvsGG58OUv3jw576ageDbHJ7uF8qId", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:438", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:439", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:jJtba-g244xgKn9VpNPPG4pYrDjroSCP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.r4_0KPC2QwJjEZRfWUZFgbp0LvvM9IYY", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:439", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:440", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:NNsjQDEXHOTq5uMwuKrxJB-Pyl166eNT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.6ZS84FXRs9aO5v0z-XrD3UPSBr3DivZf", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:440", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:441", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:LS8uHfMp0ISLHv7Fwe_o4P-xon6djnD-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.PvT5_Upp-jCGI6xDiihgx3uzOjZcVLpu", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:441", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:442", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:PVD_0cKV8NAX8-LuPi48MMcx1Y8Tq1i7", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.6404Vhjkm9RlB6Mgv5JfQ4LPiV3jaseU", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:442", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:443", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:BbnnHPgKQqUDbJ8Rd3RhRvRH8Ml-sv4P", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CMcJNS2hl5LwQd2mDCHwPZowQ8JhCuE3", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:443", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:444", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:rcC7UdkYmkxfdTq5qQ-EKPOk0RmqHgYS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CVBMOLB83i86owaBt636xVhdQ7aeTfyf", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:444", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:445", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:rcC7UdkYmkxfdTq5qQ-EKPOk0RmqHgYS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CVBMOLB83i86owaBt636xVhdQ7aeTfyf", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:444", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:446", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:ENiF4KGA43L2hK0INOjndzE9ZF9eY7EA", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3WBJ-GVXkDEc8saOc44B7SJTHGNTjLOq", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:446", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:447", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:161", "type": "Document", "label": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1200/JCO.2007.14.4956"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:18390968", "doi:10.1200/JCO.2007.14.4956"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:nIhQEpCMlZEXr8ygEUaiEJiTs8t88Ap_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RI834ljUlgAn9ez2JG32bVVchgx-t7Pp", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "subject_descriptor": "moa.variant:447", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AMEL", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["oncotree:MEL"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "moa.normalize.therapy:Selumetinib", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2289380"}}
{"id": "moa.assertion:460", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Avapritnib inhibited the autophosphorylation of PDGFRA p.D842V in cellular assays.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:137", "type": "Document", "label": "Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf. Accessed September 2nd, 2021.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:b1YQ5mDSYMRXnsbBhz6BYIIPSOlU6274", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2272107", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "subject_descriptor": "moa.variant:459", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AGIST", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["oncotree:GIST"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "moa.normalize.therapy:Avapritinib", "type": "TherapeuticDescriptor", "label": "Avapritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2272107"}}
{"id": "moa.assertion:462", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to avapritinib, a KIT inhibitor, for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor alpha (PDGFRA) exon 18 variant, including PDGFRA p.D842V.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:137", "type": "Document", "label": "Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf. Accessed September 2nd, 2021.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:b1YQ5mDSYMRXnsbBhz6BYIIPSOlU6274", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2272107", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "subject_descriptor": "moa.variant:459", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AGIST", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["oncotree:GIST"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "moa.normalize.therapy:Avapritinib", "type": "TherapeuticDescriptor", "label": "Avapritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "therapeutic": "rxcui:2272107"}}
{"id": "moa.assertion:467", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:hHAoIBGjl8blC2VX-TVrvFkBxLY9IpRW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4BYZppCvYIbPaKyAkn4KA9fjgfdPnd7Z", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:467", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:468", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1V-ldZDmN0I2KT71cy0NqU5ZFCcOc8xl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gSEj555FrQu0uZMZcSDcGpE5p5TdBwX7", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:468", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:469", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:9SH5XgO2Viopm8MPdbYXt2TeyWKCB6xZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:469", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:470", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:DA2pecZO2Hu_xl6c6_-CKAdD22DcLfgE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.X0Z-pr_A1Sy49Qd6DJ4-5dquPGfTseHU", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:470", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:471", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:dp7XVq8bSd05cRdhqHWZi79ysF6nWm_D", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gGHSvgtjj8086ObJm6ZfIa68KR0CT_VO", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:471", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:472", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:t0L2IlZ6uT3x6oAreAyfQkQ67X5LqJVt", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3kGBMsAR03qZ0_EQ6Ts1xP5lXvwYetEY", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:472", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:473", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:t0L2IlZ6uT3x6oAreAyfQkQ67X5LqJVt", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3kGBMsAR03qZ0_EQ6Ts1xP5lXvwYetEY", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:472", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:474", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:8sSlCgcsdzcOAzyqD9KP8cJ0V_rwil5s", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.7NSMwTRR_yBpn8GqpL2Ux_8OD5PbOqjC", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:474", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:475", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Ky7jX4BAtlHqspbQOAdnSinxISuohoE-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:475", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:476", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:DbAa5szfIykHgF7GTLD6COzmlnirsuDM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.vxWenCx5Zh7thv9vYTHJsjn12LIMFve1", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:476", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:477", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:UBs38cSC0th5DK0Whu6GxBJxN8oAwF81", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.i-AkFhlrTP9m7d-5LUmOKR1qizXjdjM4", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:477", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:478", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:N5CBJ1ZO62JAQhHx5dp2JzT8p1kfW92t", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.mCpnGyjIgv27feD0L-LFc95zm7d6RmDt", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:478", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:479", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:JsAQ9sCLJ6UaeouIANMY6PjM2cIlt-rn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:479", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:480", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:-40Nl2iqNjzWaSF21DvkNMoFwDAfT-3X", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.1fhSfLxaMG3SWi4nUQkvFchAtKtRh9_p", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:480", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:481", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:5NBQrOMyEAhwToodaBx_nkJIfzgg2DWM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wGsmoMRwSDazdAyurTnARM61XWCkKRHc", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:481", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:482", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:0nX50U94hlGt1aRsYQpB4RWSkdKTTcPx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.bxC8DxNJMy76trFNcDtsH2X6pF23Ze5r", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:482", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:483", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:0nX50U94hlGt1aRsYQpB4RWSkdKTTcPx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.bxC8DxNJMy76trFNcDtsH2X6pF23Ze5r", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:482", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:484", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:qiECReNLhhXsAlv4p2BVlzy-_hQK1KU-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.33_VKxgbW1TazQGgEQUC2H6PmMZ6F-v2", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:484", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:485", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:4CcS-ullGUzLZTsVjb-P0LqnjJnymhwM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nyuWYXXVPT_eO8mWhz_HvPXsS5rPrazX", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:485", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:486", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:58", "type": "Document", "label": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1158/1078-0432.CCR-09-2828"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:20453058", "doi:10.1158/1078-0432.CCR-09-2828"]}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:EbxiZ6S3iwhdkrok5bQUa3bNklOgVADl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.fDgjmQ6zm6yehkeGtfa-Ykqgy-QKnxVg", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9245", "type": "Disease"}}, "subject_descriptor": "moa.variant:486", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ABRCA", "type": "DiseaseDescriptor", "label": "Invasive Breast Carcinoma", "xrefs": ["oncotree:BRCA"], "disease": "ncit:C9245"}, "object_descriptor": {"id": "moa.normalize.therapy:Pictilisib", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "moa.assertion:529", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Certain missesnse mutations may predict resistance to RET inhibitors", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:173", "type": "Document", "label": "Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1093/annonc/mdy137"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:29912274", "doi:10.1093/annonc/mdy137"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:TZdDVOhLTJGxKIrfRiEBf5EHuFTMXKDO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.9ibuOLww1-x_kykE-sbtIRUr8SZhJSex", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2370147", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3879", "type": "Disease"}}, "subject_descriptor": "moa.variant:529", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ATHME", "type": "DiseaseDescriptor", "label": "Medullary Thyroid Cancer", "xrefs": ["oncotree:THME"], "disease": "ncit:C3879"}, "object_descriptor": {"id": "moa.normalize.therapy:LOXO-292", "type": "TherapeuticDescriptor", "label": "LOXO-292", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:2370147"}}
{"id": "moa.assertion:530", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Certain missesnse mutations may predict sensitivity to RET inhibitors", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:173", "type": "Document", "label": "Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://doi.org/10.1093/annonc/mdy137"}, {"type": "Extension", "name": "source_type", "value": "Journal"}], "xrefs": ["pmid:29912274", "doi:10.1093/annonc/mdy137"]}], "evidence_level": {"id": "vicc:e00007", "type": "Coding", "label": "observational study evidence"}, "target_proposition": {"id": "proposition:GaVkMvFwci4h3o-nk6Io6W6XYTNcfoiR", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ld4IL6kursGxjcAXopnYRTKKS-06pP8-", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2370147", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3879", "type": "Disease"}}, "subject_descriptor": "moa.variant:530", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3ATHME", "type": "DiseaseDescriptor", "label": "Medullary Thyroid Cancer", "xrefs": ["oncotree:THME"], "disease": "ncit:C3879"}, "object_descriptor": {"id": "moa.normalize.therapy:LOXO-292", "type": "TherapeuticDescriptor", "label": "LOXO-292", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "therapeutic": "rxcui:2370147"}}
{"id": "moa.assertion:822", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:251", "type": "Document", "label": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf. Revised May 2022. Accessed July 7th, 2022.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:JiKWgplj0PQYD0joZkhJM_C8fTKZ2ZyY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cXxt95ehS1vnyR-ZKhMNpx2eKUX136uo", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2049873", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "subject_descriptor": "moa.variant:323", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AAML", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["oncotree:AML"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "moa.normalize.therapy:Ivosidenib", "type": "TherapeuticDescriptor", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "disease": "ncit:C4436"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "therapeutic": "rxcui:2049873"}}
{"id": "moa.assertion:823", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:251", "type": "Document", "label": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf. Revised May 2022. Accessed July 7th, 2022.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:XzhdxvwlwRCnwF5SATQDFHseoCCFLXYL", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rNhxmp_gYSRocQWOzkt83kNujGnV-BVj", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2049873", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "subject_descriptor": "moa.variant:324", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AAML", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["oncotree:AML"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "moa.normalize.therapy:Ivosidenib", "type": "TherapeuticDescriptor", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "disease": "ncit:C4436"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "therapeutic": "rxcui:2049873"}}
{"id": "moa.assertion:824", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:251", "type": "Document", "label": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf. Revised May 2022. Accessed July 7th, 2022.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:IpXOZAz-3feVy-xXA-PB_V0CEUfaPWWm", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cXxt95ehS1vnyR-ZKhMNpx2eKUX136uo", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2049873", "type": "Therapeutic"}, {"id": "rxcui:1251", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "subject_descriptor": "moa.variant:323", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AAML", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["oncotree:AML"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "moa.tcd:q8-EQ3sEvpFi9GFxwRkBI4-kW-qt4Ka0", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2049873", "type": "Therapeutic"}, {"id": "rxcui:1251", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Ivosidenib", "type": "TherapeuticDescriptor", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "disease": "ncit:C4436"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "therapeutic": "rxcui:2049873"}, {"id": "moa.normalize.therapy:Azacitidine", "type": "TherapeuticDescriptor", "label": "Azacitidine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:583", "type": "DiseaseDescriptor", "label": "Chronic myelomonocytic leukemia", "disease": "ncit:C3178"}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}]}}], "therapeutic": "rxcui:1251"}]}}
{"id": "moa.assertion:825", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.", "specified_by": "metakb.method:4", "is_reported_in": [{"id": "moa.source:251", "type": "Document", "label": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf. Revised May 2022. Accessed July 7th, 2022.", "extensions": [{"type": "Extension", "name": "source_url", "value": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf"}, {"type": "Extension", "name": "source_type", "value": "FDA"}]}], "evidence_level": {"id": "vicc:e00002", "type": "Coding", "label": "FDA recognized evidence"}, "target_proposition": {"id": "proposition:46y4tWQyzoY3eBCBr-7OZ7BLJ7pmjK6E", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rNhxmp_gYSRocQWOzkt83kNujGnV-BVj", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2049873", "type": "Therapeutic"}, {"id": "rxcui:1251", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "subject_descriptor": "moa.variant:324", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "moa.normalize.disease:oncotree%3AAML", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["oncotree:AML"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "moa.tcd:q8-EQ3sEvpFi9GFxwRkBI4-kW-qt4Ka0", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2049873", "type": "Therapeutic"}, {"id": "rxcui:1251", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "moa.normalize.therapy:Ivosidenib", "type": "TherapeuticDescriptor", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "disease": "ncit:C4436"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "therapeutic": "rxcui:2049873"}, {"id": "moa.normalize.therapy:Azacitidine", "type": "TherapeuticDescriptor", "label": "Azacitidine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:583", "type": "DiseaseDescriptor", "label": "Chronic myelomonocytic leukemia", "disease": "ncit:C3178"}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}]}}], "therapeutic": "rxcui:1251"}]}}